Moderna, it could speed up global inoculation if it proves effective.
Speaking at J.P. Morgan’s health care investor conference on Monday, Johnson & Johnson CEO Alex Gorsky said that the company aimed to have “hundreds of millions of doses” of the vaccine available in the first half of this year, and “close to one billion” by the end of the year.
“We’re still on track to be able to achieve those volumes,” Gorsky said. “And again, we’re working night and day to see what else can we do to accelerate that even more in an effective and safe, compliant, high-quality manner.”
Order Reprints
Here’s what you need to know to navigate the markets today.
• The House voted 232 to 197 to impeach President Donald Trump for “incitement of insurrection.” The vote was largely along party lines, with 10 Republicans joining House Democrats in support of impeachment. Trump has now become the first president in U.S. history to be impeached twice. Andrew Johnson and Bill Clinton are the only other presidents in U.S. history to be impeached. Trump was impeached on Dec. 19, 2019, for abuse of power and obstruction of justice for.
Close
Here’s what you need to know to navigate the markets today.
Order Reprints Print Article
Among other factors, Barron’s Roundtable members say the successful distribution of a Covid-19 vaccine will fuel even further gains for the stock market. STR/AFP/Getty Images Text size
With a year unlike any other in the rearview mirror, the members of
Barron’s investment Roundtable foresee an economy still in recovery in 2021 though one with plenty of opportunities for investors.
Rupal Bhansali, Sonal Desai, Abby Joseph Cohen, Mario Gabelli, Todd Ahlsten, James Anderson, Henry Ellenbogen, Meryl Witmer, Bill Priest, and Scott Black shared their outlooks on the economy and markets with
Barron’s Roundtable Q&A session. The group convened Monday for its annual Barron’s investment Roundtable discussion, which will be covered in depth in
Order Reprints Text size
Moderna’s Covid-19 vaccines are currently being distributed across the U.S. Joseph Prezioso / AFP via Getty Images
Moderna’s chief medical officer said Monday that the company expects that its Covid-19 vaccine should provide protection from the virus for a year or more.
Speaking Monday afternoon at a health-care investor conference hosted by
J.P. Morgan, Moderna (ticker: MRNA) Chief Medical Officer Tal Zaks said that the company will be tracking early recipients of the vaccine to try to determine how long the initial two-dose regimen will be effective.
“From what we’ve seen so far, I think our expectation is that the vaccination should last you at least a year,” Zaks said. “We have to follow people until we see the year. We’ll try and boost some of them to see how well a boost works.”